Fate Therapeutics (FATE) Bullish Stance Reiterated at BMO Capital Following Meetings

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $15 price target on Fate Therapeutics (NASDAQ: FATE) following meetings with management.

Birchenough commented, "We maintain our view that FATE has an attractive and undervalued platform addressing both near-term and long-term opportunities. Use of PROHEMA to improve stem cell function may have a profound impact on post-transplant infection control and non-disease related mortality in oncology and morbidity secondary to inherited metabolic disorders with specific focus on neurological outcome. PROTMUNE extends the concept to CD34+ve cells where additional properties such as PD-L1, ICOS or CXCR4 expression can be toggled to change the immune profile of stem cells as desired. Ultimately, however, the ability to use a designer off-the-shelf iPSC as a platform for final product modification and then differentiation into the desired cell type offers the possibility for broad application of cellular therapy that cannot be achieved with current autologous approaches."

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $6.05 yesterday.

You May Also Be Interested In

• Coinbase (COIN) PT Raised to $212 at Cantor Fitzgerald
• Five9, Inc (FIVN) PT Raised to $40 at Truist Securities
• GitLab Inc (GTLB) PT Raised to $45 at DA Davidson